Moderna and Merck said their personalized mRNA cancer vaccine, intismeran autogene, showed promising results in a late-stage clinical trial involving more than 1,000 patients. Used after surgery for localized melanoma, the vaccine reduced the risk of cancer recurrence or spread to other parts of the body. Full trial data have not yet been released, but researchers and cancer specialists see the result as a possible breakthrough for patient-specific therapeutic vaccines.
The companies formally partnered on cancer vaccines in 2016, with Merck investing $200 million that year and another $250 million in 2022. The vaccine was used with Keytruda, which helps immune T-cells become active against cancer cells. Researchers say the treatment analyzes a patient’s tumor genetics and trains the immune system to recognize up to 34 cancer targets.
US approval could be possible next year if the vaccine is successfully cleared. Researchers are also examining whether the method can work in cancers with fewer genetic mutations, including lung, kidney and pancreatic cancers. Moderna and Merck are further analyzing melanoma data to improve effectiveness, while Moderna’s chief executive said the current version is not the final version.
ক্যানসারের চিকিৎসায় শত বছরের ব্যর্থতার পর নতুন আশার আলো দেখিয়েছে মডার্না ও মার্কের যৌথ উদ্যোগে তৈরি একটি ব্যক্তিকেন্দ্রিক এমআরএনএ ক্যানসার টিকা। প্রাথমিক পর্যায়ের নয়, বরং শেষ ধাপের পরীক্ষায় এই প্রথম কোনো থেরাপিউটিক ক্যানসার টিকা সফলতার ইঙ্গিত দিয়েছে।
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
